Herein, we identified that the third-generation EGFR inhibitor ASK120067 exhibited potency against B-cell lymphoma and T-cell leukemia by targeting BTK and ITK, respectively. This evidence concerns the gene ITK and B-cell non-Hodgkin lymphoma.